• Syndax priced a private placement of USD 250 million of 2.25% convertible senior notes due 2031.
• Closing expected June 10, 2026; net proceeds estimated at about USD 243 million.
• Notes convert at 40 shares per USD 1,000; initial conversion price about USD 24.76, a 35% premium to June 3 close.
• Proceeds earmarked for general corporate purposes, including R&D, working capital, commercialization, business development.
• Redeemable from June 20, 2029, subject to stock-price trigger; holders can require repurchase on a fundamental change.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606040700PRIMZONEFULLFEED9731691) on June 04, 2026, and is solely responsible for the information contained therein.